Skip to main content

Table 3 Immunological and virological response to ART among all ART-naïve adolescents and perinatally infected adolescents (9-19 years) compared with that of young adults (20-28 years)

From: Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa

Characteristics All ART-naïve adolescents
N = 64
ART-naïve young adults
N = 715
P-value† ART-naïve perinatally-infected adolescents N = 31 P-value†
Baseline CD4 (cells/μL), median (IQR) 139 (62-198) 117 (59-170) 0.15 170 (78-228) 0.026
CD4 (cells/μL), median (IQR) change from baseline      
16 weeks 220 (133.5-314) 121 (67-199) 0.0001 188.5 (126-322) 0.0004
32 weeks 195 (136-439) 155 (97-238) 0.0008 256 (172-487) 0.0002
48 weeks 373 (255-518) 187 (118-285) 0.0001 374 (242-631) 0.0002
Virological suppression*, n(%)      
16 weeks 36 (97.3) 490 (89.6) 0.13 27 (100.0) 0.077
32 weeks 12 (37.5) 331 (75.1) < 0.001 7 (28.0) < 0.001
48 weeks 9 (27.3) 270 (63.1) < 0.001 6 (24.0) < 0.001
  1. †The p values were compared with young adults and calculated using Wilcoxon rank-sum test for continuous variables and fishers exact test for binary variables.
  2. *The denominators at 16 weeks for all ART-naïve adolescents, perinatally infected adolescents and young adults were 37, 27 and 547 respectively; at 32 weeks was 32, 25 and 440 respectively and at 48 weeks was 33, 25 and 427 respectively.